Spero Therapeutics(SPRO) - 2024 Q2 - Quarterly Results

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update • Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); preliminary data expected in 4Q 2024 • New SPR720 in-vitro resistance data to be presented at IDWeek 2024 conference in October • Company announces departure of Chief Medical Of icer Kamal Hamed, MD, MPH, MBA; Appoints Board member and Chair of Development Committe ...